S&P 500 and Nasdaq 100 Breaking Out We are seeing signs that this 2+ month consolidation in the S&P 500 and Nasdaq 100 (QQQ) is ready to break out to the upside. Part of that is the obvious; both the SPX and QQQ are breaking out to marginal new highs. The other part that has kept us bullish this whole time is that market dynamics have remained risk-on, which we have discussed on a weekly basis. Bottom line: our outlook remains bullish as long as the S&P 500 remains above 5770-5850. Our recommen...
A director at Adtalem Global Education Inc sold 4,812 shares at 103.257USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Local Tops for 10-Year Yield, DXY, and WTI Crude Oil Our outlook remains bullish, and since late-December we have been suggesting to use the pullback as a buying opportunity. Our most recent and highest conviction "buy the dip" call came last week (1/14/25 Compass) amid all the major indexes testing key supports (S&P 500, Nasdaq 100, DJI, S&P Mid Caps, VXF, Russell 2000, ARKK, and SMH), bullish breadth divergences, and other ongoing risk-on signals. Those dip buys are finally paying off, with a...
A director at Gilead Sciences Inc sold/sold after exercising options 8,500 shares at 91.960USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...
Moody's Ratings ("Moody's") affirmed Adtalem Global Education Inc.'s ("Adtalem"), a Chicago, Illinois-based provider of post-secondary education and professional talent to the healthcare industry, Ba3 corporate family rating ("CFR") and its Ba3-PD probability of default rating. Concurrently, we affi...
A director at Costar Group Inc sold 5,500 shares at 79.880USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Continue to Ride the Trend Higher Our outlook remains bullish and the significant end-of-year rally that we have been expecting since mid-October is in full swing; continue to ride the trend higher. Our election day Compass report (11/5/24) was titled "Buy the Pullback," and last week's Compass (11/19/24) was similarly titled "Buy the Pullback Again" considering our expectation for support at the 20-day MAs on the Russell 2000 (IWM), S&P 500, and Nasdaq 100 (QQQ) with small- and mid-caps likely...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Moody's Ratings (Moody´s) assigned an A3 rating to the new senior unsecured notes issuance of Gilead Sciences, Inc. ("Gilead"). There are no changes to Gilead's existing ratings including the A3 senior unsecured ratings, (P)A3 senior unsecured shelf or the stable outlook. Proceeds of the offering ...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 17 October 2024 in which we reassessed the appropriateness of the ratings in the cont...
Upgrading Health Care to Market Weight Breadth continues to improve and Russell 2000 (IWM) small-caps and the Dow remain bullish, all while the S&P 500 and Nasdaq 100 (QQQ) are going through a pullback/consolidation phase. Considering the Russell 2000 vs. S&P 500 ratio is reversing a 3.5-year downtrend, we expect this trend of small-cap outperformance to continue for months or longer. We will maintain our bullish view on small-caps (IWM) and the Dow as long as they remain above $210 and 39,800,...
Global oncology spending is projected to reach US$409bn by 2028E, up from US$223bn in 2023A at a 5yr CAGR of 11.5-14.5% from 2024-2028 (IQVIA, 2024). This growth is in part driven by US spending, which has increased to $99bn in 2023A up from $65bn in 2019A - the US makes up ~45% of global oncology spending.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.